Claims for Patent: 6,284,730

Summary for Patent: 6,284,730

Title:	Methods useful in the treatment of bone resorption diseases
Abstract:	The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
Inventor(s):	Dietrich; John (Etobicoke, CA), Ljunghall; Sverker (Uppsala, SE), Sjogren; Sven (Billdal, SE)
Assignee:	NPS Allelix Corp. (Mississauga, CA)
Application Number:	09/125,247
Patent Claims:	1. A method useful in the treatment of bone resorption diseases comprising administering to a mammal in need of such treatment or at increased risk to suffer from such disease: (a) an effective amount of parathyroid hormone during a period of approximately 6 to 24 months; and (b) after the administration of parathyroid hormone has been terminated, an effective amount of a bone resorption inhibitor during a period of approximately 6 to 36 months. 2. The method according to claim 1, adapted for said administration of parathyroid hormone for approximately 12 to 24 months. 3. The method according to claim 2, adapted for said administration of parathyroid hormone for approximately 18 months. 4. The method according to any one of claims 1, 2, or 3, adapted for said administration of bone resorption inhibitor for approximately 12 to 36 months. 5. The method according to claim 4, adapted for said administration of bone resorption inhibitor for approximately 12 to 18 months. 6. The method according to claim 5, adapted for said administration of bone resorption inhibitor for approximately 12 months. 7. The method according to any one of claims 1, 2, or 3, wherein said parathyroid hormone is selected from the group consisting of: (a) full-length parathyroid hormone; (b) biologically active variants of full-length parathyroid hormone; (c) biologically active parathyroid hormone fragments; and (d) biologically active variants of parathyroid hormone fragments. 8. The method according to any one of claims 1, 2, or 3, wherein the bone resorption inhibitor is selected from the group consisting of a biphosphonate, a selective estrogen receptor modulator, calcitonin, a vitamin D analog, and a calcium salt. 9. The method according to any one of claims 1, 2, or 3 for the treatment of osteoporosis. 10. The method of claim 4, wherein the parathyroid hormone is selected from the group consisting of: (a) full-length parathyroid hormone; (b) biologically active variants of full-length parathyroid hormone; (c) biologically active parathyroid hormone fragments; and (d) biologically active variants of parathyroid hormone fragments. 11. The method of claim 5, wherein the parathyroid hormone is selected from the group consisting of: (a) full-length parathyroid hormone; (b) biologically active variants of full-length parathyroid hormone; (c) biologically active parathyroid hormone fragments; and (d) biologically active variants of parathyroid hormone fragments. 12. The method of claim 6, wherein the parathyroid hormone is selected from the group consisting of: (a) full-length parathyroid hormone; (b) biologically active variants of full-length parathyroid hormone; (c) biologically active parathyroid hormone fragments; and (d) biologically active variants of parathyroid hormone fragments. 13. The method of claim 4, wherein the bone resorption inhibitor is selected from the group consisting of a biphosphonate, estrogen, a selective estrogen receptor modulator, calcitonin, a vitamin D analog, and a calcium salt. 14. The method of claim 5, wherein the bone resorption inhibitor is selected from the group consisting of a biphosphonate, estrogen, a selective estrogen receptor modulator, calcitonin, a vitamin D analog, and a calcium salt. 15. The method of claim 6, wherein the bone resorption inhibitor is selected from the group consisting of a biphosphonate, estrogen, a selective estrogen receptor modulator, calcitonin, a vitamin D analog, and a calcium salt. 16. The method of any one of claims 1, 2, or 3, wherein the bone resorption inhibitor is selected from the group consisting of alendronate, estrogen, raloxifene, tamoxifene, droloxifene, toremifene, idoxifene, levormeloxifene, and calcitonin. 17. The method of claim 4, wherein the bone resorption inhibitor is selected from the group consisting of alendronate, estrogen, raloxifene, tamoxifene, droloxifene, toremifene, idoxifene, levormeloxifene, and calcitonin. 18. The method of claim 5, wherein the bone resorption inhibitor is selected from the group consisting of alendronate, estrogen, raloxifene, tamoxifene, droloxifene, toremifene, idoxifene, levormeloxifene, and calcitonin. 19. The method of claim 6, wherein the bone resorption inhibitor is selected from the group consisting of alendronate, estrogen, raloxifene, tamoxifene, droloxifene, toremifene, idoxifene, levormeloxifene, and calcitonin. 20. The method of claim 4 for the treatment of osteoporosis. 21. The method of claim 5 for the treatment of osteoporosis. 22. The method of claim 6 for the treatment of osteoporosis. 23. The method of claim 7 for the treatment of osteoporosis. 24. The method of claim 8 for the treatment of osteoporosis. 25. The method of any one of claims 1, 2, or 3, wherein the mammal is a human. 26. The method of claim 6, wherein the mammal is a human. 27. The method of claim 7, wherein the mammal is a human. 28. The method of claim 8, wherein the mammal is a human. 29. The method of claim 9, wherein the mammal is a human.

Details for Patent 6,284,730

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2017-06-19